free web stats

Invokana / Farxiga / Jardiance / Invokamet / Xigduo / Glyxambi / Synjardy / Qtern

 

In a rush? You can use our Quick Contact Form to tell us the basic information about your case.

 

Ketoacidosis, Acute Kidney Injury, Kidney Failure, Heart Attacks, Strokes, DVT / PE, and Other Side Effects Linked to These Diabetes Drugs

 
The FDA is investigating a connection between Invokana, Farxiga, and Jardiance, as well as Invokamet, Xigduo, Glyxambi, Synjardy, and Qtern with these various medical complications as drug side effects:

  • Diabetic Ketoacidosis (DKA)
  • Ketoacidosis
  • Ketosis
  • Acute Kidney Injury
  • Kidney Failure / Renal Failure
  • Kidney Damage
  • Pyelonephritis (kidney infection)
  • Urosepsis (blood infection)
  • Urinary Tract Infection (UTI)
  • Heart Attacks / Myocardial Infarctions (MI)
  • Ischemic Stroke / Cerebrovascular Accident (CVA)
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Heart Failure
  • Leg Amputation
  • Foot or Toe(s) Amputation

All of these diabetes drugs are Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, a new class of diabetes medicines.

As regards the ketoacidosis side effects, it is important to know that if diabetic ketoacidosis (DKA) is not treated, it can lead to severe illness or death. In more detail, possible complications of DKA include these medical conditions:

  • Cerebral Edema (fluid buildup in the brain)
  • Bowel Necrosis (death of bowel tissue due to low blood pressure)

We are currently investigating possible drug injury lawsuits against the responsible pharmaceutical companies for diabetes patients who have developed any of the medical conditions listed above. For example:

Invokana – Foot Amputation – 52 yr old man
Jardiance – Diabetic Ketoacidosis (DKA) – 51 yr old woman
Glyxambi – Diabetic Ketoacidosis (DKA) – 54 yr old man
Jardiance – Diabetic Ketoacidoisis (DKA) – 60 yr old woman
Invokana – Acute Kidney Disease – 46 yr old man
Jardiance – Diabetic Ketoacidosis (DKA) – 60 yr old woman
Farxiga – Liver Failure and Transplant; Renal Failure – 48 yr old woman
Farxiga – Diabetic Ketoacidosis (DKA) – 27 yr old woman
Jardiance – Stroke – 60 yr old woman
Farxiga – Heart Failure – 64 yr old man

__________________________________________________________

Diabetes Drugs Side Effects Case Evaluation

We encourage you to submit a Drug Injury Law Case Review – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.

___________________________________________________________

List of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors Currently Available in the US

Invokana (canagliflozin) — Janssen Pharmaceuticals — FDA Approval: 2013
Invokamet (canagliflozin and metformin) — Janssen Pharmaceuticals — FDA Approval: 2014
Invokamet XR (canagliflozin and metformin extended-release) — Janssen Pharmaceuticals — FDA Approval: 2016
Farxiga (dapagliflozin) — AstraZeneca Pharmaceuticals — FDA Approval: 2014
Xigduo XR (dapagliflozin and metformin extended-release) — AstraZeneca Pharmaceuticals — FDA Approval: 2014
Qtern (dapagliflozin and saxagliptin) AstraZeneca Pharmaceuticals — FDA Approval: 2017
Jardiance (empagliflozin) — Boehringer Ingelheim Pharmaceuticals — FDA Approval: 2014
Glyxambi (empagliflozin and linagliptin) — Boehringer Ingelheim Pharmaceuticals — FDA Approval: 2015
Synjardy (empagliflozin and metformin hydrochloride) — Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company — FDA Approval: 2015
Synjardy XR (empagliflozin and metformin hydrochloride) — Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company — FDA Approval: 2016

__________________________________________________________

Jardiance, Invokana, And Farxiga Double Risk Of Diabetic Ketoacidosis

The June 8, 2017 edition of The New England Journal of Medicine (NEJM) has a “To the Editor” letter, titled “Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor”, which is likely causing some concerns among doctors and type 2 diabetes (T2D) patients. It is about the safety of Jardiance, Invokana, Farxiga, and other diabetes medicines in the SGLT2 inhibitor class of diabetes drugs.

A June 7, 2017 MedPage Today article, “Study Warns of Diabetic Ketoacidosis With SGLT2 Inhibitors in T2D”, provides a summary and some commentary about the recent medical study which is described in this June 2017 NEJM letter to the editor:

The newest class of drugs for treating type 2 diabetes carries a greater risk for diabetic ketoacidosis compared to other classes of drugs, a new study suggests.

Newly initiated use of an SGLT2 inhibitor was associated with a roughly twofold greater risk of diabetic ketoacidosis versus new initiation of a DPP4 inhibitor (HR 2.2, 95% CI 1.4 to 3.6), according to Michael Fralick, MD, of Brigham and Women’s Hospital, and colleagues….

It is important to know that if diabetic ketoacidosis (DKA) is not treated, it can lead to severe illness or death. In more detail, possible complications of DKA include these medical conditions:

  • Cerebral Edema (fluid buildup in the brain)
  • Bowel Necrosis (death of bowel tissue due to low blood pressure)

All of these newer diabetes medicines are part of the Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors class of drugs:

Invokana (canagliflozin)
Invokamet (canagliflozin and metformin)
Invokamet XR (canagliflozin and metformin extended-release)
Farxiga (dapagliflozin)
Xigduo XR (dapagliflozin and metformin extended-release)
Qtern (dapagliflozin and saxagliptin)
Jardiance (empagliflozin)
Glyxambi (empagliflozin and linagliptin)
Synjardy (empagliflozin and metformin hydrochloride)
Synjardy XR (empagliflozin and metformin hydrochloride)

We are currently investigating possible drug injury lawsuits against the responsible pharmaceutical companies for diabetes patients who have developed diabetic ketoacidosis (DKA), with or without cerebral edema and bowel necrosis.

[Read this article in full at original source]

Earlier Invokana / Farxiga / Jardiance articles by attorney Tom Lamb on the Side Effects Blog:

____________________________________________________________

Free Diabetes Drugs Side Effects Case Evaluation >>

____________________________________________________________

All content by attorney Tom Lamb

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, NC 28403
(800) 426-9535
ThomasJLamb@DrugInjuryLaw.com
Disclaimer and Copyright